Effect of highly purified eicosapentaenoic acid (EPA) for patients with multiple artery atherosclerotic risk factors and clinical usefulness of the ratio of serum EPA to arachidonic acid (AA) as the indicator of therapy effect of atherosclerosis

Therapeutic Research

Volumn 35, Issue 2, 2014, Pages 177-182

  Maeda, Kazuo ^a  

^a Maeda Medical Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ARACHIDONIC ACID; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID;

ADD ON THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL;

EID: 84896540775     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. LaRosa JC, Grundy SM, Waters D.D., Shear C., Barter P, Fruchart JC, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-35.
2. Baigent C, Keech A, Kearney P.M., Blackwell L., Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-78.
3. Alagona P Jr. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care 2009; 15(3 Suppl):S65-73.
4. Yokoyama M, Origasa H, Matsuzaki M., Matsuzawa Y, Saito Y, Ishikawa Y., et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients(JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-8.
5. Saito Y, Yokoyama M, Origasa H., Matsuzaki M, Matsuzawa Y, Ishikawa Y., et al.; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200(1):135-40.
6. Ishikawa Y, Yokoyama M, Saito Y., Matsuzaki M, Origasa H, Oikawa S., et al.; JELIS Investigators. Preventive Effects of Eicosapentaenoic Acid on Coronary Artery Disease in Patients With Peripheral Artery Disease: subanalysis of the JELIS Trial. Circ J 2010; 74:1451-7.
7. Bots ML, Hoes AW, Koudstaal P.J., Hofman A., Grobbee DE Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96(5):1432-7.
8. O'Leary D.H., Polak JF, Kronmal R.A., Manolio TA, Burke GL, Wolfson SK Jr. Carotidartery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340(1): 14-22.
9. Mita T, Watada H, Ogihara, Nomiyama T, Ogawa O, Kinoshita J, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 2007; 191 (1):162-7.
10. Matsuzaki M, Yokoyama M, Saito Y., Origasa H, Ishikawa Y, Oikawa S., et al.; JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Cire J 2009; 73 (7): 1283-90.
11. Ueeda M, Doumei T, Takaya Y., Shinohata R, Katayama Y, Ohnishi N., et al. Serum N-3 polyunsaturated Fatty Acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction. Circ J 2008; 72(11): 1836-43.
12. Terano T Salmon JA, Moncada S. Biosynthesis and biological activity of leukotriene B5. Prostaglandins 1984; 27(2):217.
13. Arita M, Bianchini F, Aliberti J., Sher A, Chiang N, Hong S., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin El. J Exp Med 2005; 201 (5):713-22.
14. Satoh N, Shimatsu A, Kotani K., Sakane N, Yamada K, Suganami T., et al. Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome. Diabetes Care 2007; 30(1):144-6.
15. Itoh M, Suganami T Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vase Biol 2007; 27 (9);1918-25.